Business
Isodiol International Inc. Announces Letter of Intent to Supply 99.5%+ Pharma-Grade Cannabidiol to Zenabis
Isodiol International Inc. Announces Letter of Intent to Supply 99.5%+ Pharma-Grade Cannabidiol to Zenabis.
About this update from Isodiol International Inc
[{"type":"text","content":"\n \n Isodiol \n International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) \n (the “Company” or “Isodiol”), a global innovator specializing in the \n development of pharmaceutical and wellness products, is pleased to \n announce that it has signed a Letter of Intent (“LOI”) with Zenabis Ltd. \n (“Zenabis ”), one of Canada’s largest Licensed Producers, to import CBD \n isolate as an Active Pharmaceutical Ingredient, into Canada from \n Isodiol’s GMP-certified production facility in the United Kingdom.\n \n \n Zenabis is a Canadian biopharmaceutical company positioned to become one \n of the largest cannabis producers in Canada, with facilities totalling \n more than 400,000 square feet of cannabis production space. Zenabis \n intends to import a minimum of 3,000 g of such CBD isolate per month for \n the purposes of R&D and new product formulation.\n \n \n Marcos Agramont, CEO of Isodiol, stated: “Isodiol is pleased to announce \n another supply agreement for its highest quality, pharma grade CBD \n isolate. Zenabis’s team is working on various R&D projects focused on \n developing new products and applications, and we are pleased to be a key \n partner in enabling this R&D process.”\n \n \n “We are excited to move forward with this partnership,” explained Kevin \n Coft, CEO of Zenabis. “To have a CBD isolate accompanied by an API \n status sets it apart from every other global source, and we look forward \n to be working with Isodiol in Canada on new drug development, approved \n pharmaceutical applications, research, clinical studies and trials.”\n \n \n Having met all requirements, Isodiol recently announced that the \n Company’s wholly owned subsidiary BSPG Laboratories LTD. has received \n government approval from United Kingdom’s Medicines and Healthcare \n Products Regulatory Agency (MHRA), in accordance with The Human \n Medicines Regulations 2012 (SI 2012/1916), for the manufacturing of the \n active substance Cannabidiol (CBD) under certificate number: UK API \n 48727.\n \n \n Active ingredients are the substances in drugs that are responsible for \n the beneficial health effects experienced by consumers. Regulating \n active ingredients helps to increase the quality and safety of drugs for \n ...